Heska (HSKA) & Pharmacyte Biotech (PMCB) Head to Head Analysis

Heska (NASDAQ:HSKA) and Pharmacyte Biotech (OTCMKTS:PMCB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Valuation and Earnings

This table compares Heska and Pharmacyte Biotech’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Heska $127.45 million 4.80 $5.85 million $1.42 55.56
Pharmacyte Biotech N/A N/A -$6.82 million N/A N/A

Heska has higher revenue and earnings than Pharmacyte Biotech.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Heska and Pharmacyte Biotech, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heska 0 3 1 0 2.25
Pharmacyte Biotech 0 0 0 0 N/A

Heska presently has a consensus target price of $108.33, suggesting a potential upside of 37.32%. Given Heska’s higher possible upside, equities analysts clearly believe Heska is more favorable than Pharmacyte Biotech.

Institutional and Insider Ownership

83.0% of Heska shares are held by institutional investors. Comparatively, 0.2% of Pharmacyte Biotech shares are held by institutional investors. 14.0% of Heska shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Heska has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Pharmacyte Biotech has a beta of 2.16, meaning that its stock price is 116% more volatile than the S&P 500.

Profitability

This table compares Heska and Pharmacyte Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Heska 3.63% 8.36% 6.48%
Pharmacyte Biotech N/A -74.36% -66.54%

Summary

Heska beats Pharmacyte Biotech on 9 of the 10 factors compared between the two stocks.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. The company's Other Vaccines and Pharmaceuticals segment offers a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. Heska Corporation sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.

Pharmacyte Biotech Company Profile

PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the Cannabis plant. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.